| Cat.No. | Name | Information |
|---|---|---|
| M3835 | Alirocumab | Alirocumab is a humanized IgG1 PCSK9 monoclonal antibody that can be used in the study of hypercholesterolemia. |
| M6251 | R-IMPP | R-impp (PF-00932239) is an anti-secreting inhibitor of PCSK9 (IC50=4.8 μM), which can inhibit PCSK9 protein translation by targeting the ribosomes at the time of 80S. |
| M45128 | CiVi-007 | CiVi-007 is an antisense oligonucleotide (ASO) polymerized with N-acetylglucosamine that targets PCSK9 and can be used in studies related to hypercholesterolemia. |
| M45125 | AZD-8233 | AZD-8233 is an orally active, antisense oligonucleotide (ASO) targeting PCSK9 that targets and inhibits the translation and protein synthesis of PCSK9 mRNA in hepatocytes and reduces circulating LDL-C levels. It can be used in studies related to hypercholesterolemia. |
| M25402 | Enlicitide chloride | Enlicitide (MK-0616) chloride is an oral PCSK9 macrocyclic peptide inhibitor. |
| M25092 | Recaticimab | Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia. |
| M25040 | Lerodalcibep | Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases. |
| M24997 | Tafolecimab | Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia. |
| M24651 | Ralpancizumab | Ralpancizumab is a selective PCSK9 inhibitor with potential application in hemorrhagic stroke. |
| M24650 | Bococizumab | Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
